HR 5160
Passed a chamber
Reauthorizes the Stem Cell Therapeutic and Research Act through fiscal year 2031 and replaces the fixed 150,000-unit cord blood inventory goal with a supply level set by the Secretary.
Official title: Stem Cell Therapeutic and Research Reauthorization Act of 2025
Timeline each lane is a chamber; dates pull from congress.gov actions
House
Introduced
04-SEP-2025
Referred
04-SEP-2025
Approved by committee
21-MAY-2026
Reported
02-JUL-2026
On the calendar
02-JUL-2026
Passed
20-JUL-2026
Senate
Received
21-JUL-2026
- Adds an authorization of $33,009,000 for each of fiscal years 2027 through 2031 for the C.W. Bill Young Cell Transplantation Program.
- Replaces the requirement of at least 150,000 new cord blood units with a sufficient supply, as determined by the Secretary.
- Lets the Secretary transfer cord blood units from a bank that is no longer operational or no longer meets requirements to another qualified bank or approved entity.
- Directs the Secretary to manage the size and genetic diversity of the National Cord Blood Inventory and to consider current scientific and clinical information when entering into or extending contracts.
Covers an older version. The newest CRS summary describes the bill as of "Reported to House" (02-JUL-2026); the text has changed since (Engrossed in House, 20-JUL-2026).
CRS is the Library of Congress's nonpartisan research office. Read it on congress.govHealth
■ 11 D■ 10 R
11 Democrats
10 Republicans